ALS Association - Drug Development Program

This program leverages academic scientific expertise along with industry know-how to drive the crucial transition from laboratory research project to industry drug development effort. This stage in the drug development pipeline is often underfunded because it is too late for traditional academic funding mechanisms and too early for most industry funding mechanisms. By supporting projects at this stage, the program helps fill this funding gap and has contributed to the expansion of companies and therapeutics entering ALS clinical trials.

Duration:

• 2 years

• $500,000 to support the preclinical assessment of novel or repurposed therapeutics for ALS

• Open to researchers working in industry or at academic institutions worldwide.
• Applicants should have already selected the lead therapeutic candidate they would like to test as this funding opportunity aims to support programs that have a high probability of entering the clinic within 3 years

• - Letter of Intent due on 18 December, 5 pm US ET
• - Full Proposal (by invitation only) due on 7 March 2024

• More information about the program is available here.
• LOI should be submitted though ProposalCentral
• For any other questions, please contact the Research Office